Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03740-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Ibrahim El-Serafi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. i.elserafi@ajman.ac.ae. Hauptthemen laut MEDLINE: Vidarabine, Mesothelin, Ovarian Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karolinska Institutet foundation, Cancerfonden, Cancer Society in Stockholm Research.
Abstract (Originalsprache)
In addition to their immunosuppressive effect, cytostatics conditioning prior to adoptive therapy such as chimeric antigen receptor (CAR) T cells may play a role in debulking and remodeling the tumor microenvironment. We investigated in vitro the killing efficacy and impact of treosulfan and fludarabine on ovarian cancer cells expressing mesothelin (MSLN) and effect on MSLN-targeting CAR T cells. Treosulfan and fludarabine had a synergetic effect on killing of SKOV3 and OVCAR4 cells. Sensitivity to the combination of treosulfan and fludarabine was increased when SKOV3 cells expressed MSLN and when OVCAR4 cells were tested in hypoxia, while MSLN cells surface expression by SKOV3 and OVCAR4 cells was not altered after treosulfan or fludarabine exposure. Exposure to treosulfan or fludarabine (10 µM) neither impacted MSLN-CAR T cells degranulation, cytokines production upon challenge with MSLN + OVCAR3 cells, nor induced mitochondrial defects. Combination of treosulfan and fludarabine decreased MSLN-CAR T cells anti-tumor killing in normoxia but not hypoxia. In conclusion, treosulfan and fludarabine killed MSLN + ovarian cancer cells without altering MSLN-CAR T cells functions (at low cytostatics concentration) even in hypoxic conditions, and our data support the use of treosulfan and fludarabine as conditioning drugs prior to MSLN-CAR T cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. i.elserafi@ajman.ac.ae.
- Basic Medical Sciences Department, College of Medicine, Ajman University, Ajman, UAE. i.elserafi@ajman.ac.ae.
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation, Princess Margaret Cancer Centre and University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
- Department of Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
Förderung
- Karolinska Institutet foundation
- Cancerfonden
- Cancer Society in Stockholm Research
- Karolinska Institute
Zitieren
APA
El-Serafi, I., Micallef Nilsson, I., Moter, A., Duan, Z., Mattsson, J., & Magalhaes, I. (2024). Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03740-3
Vancouver
El-Serafi I, Micallef Nilsson I, Moter A, Duan Z, Mattsson J, Magalhaes I. Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03740-3
BibTeX
@article{ElSerafi2024,
author = {El-Serafi, Ibrahim and Micallef Nilsson, Isabella and Moter, Alina and Duan, Zhe and Mattsson, Jonas and Magalhaes, Isabelle},
title = {Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03740-3}
}
EUVIMED